tetano
Editor, Senior Moderator
J Infect Dis
. 2024 Jan 12:jiad568.
doi: 10.1093/infdis/jiad568. Online ahead of print. Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters
Timothy D Carroll[SUP] 1 2 [/SUP], Talia Wong[SUP] 1 [/SUP], Mary Kate Morris[SUP] 3 [/SUP], Clara Di Germanio[SUP] 4 [/SUP], Zhong-Min Ma[SUP] 2 [/SUP], Mars Stone[SUP] 4 [/SUP], Erin Ball[SUP] 1 [/SUP], Linda Fritts[SUP] 1 2 [/SUP], Arjun Rustagi[SUP] 5 [/SUP], Graham Simmons[SUP] 4 [/SUP], Michael Busch[SUP] 4 [/SUP], Christopher J Miller[SUP] 1 2 6 [/SUP]
Affiliations
Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To better understand the mechanism of action of CCP, we studied viral replication and disease progression in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected hamsters treated with CCP obtained from recovered COVID-19 patients that were also vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. Vaxplas transiently enhanced disease severity and lung pathology in hamsters treated near peak viral replication due to immune complex and activated complement deposition in pulmonary endothelium, and recruitment of M1 proinflammatory macrophages into the lung parenchyma. However, aside from one report, transient enhanced disease has not been reported in CCP recipient patients, and the transient enhanced disease in Vaxplas hamsters may have been due to mismatched species IgG-FcR interactions, infusion timing, or other experimental factors. Despite transient disease enhancement, Vaxplas dramatically reduced virus replication in lungs and improved infection outcome in SARS-CoV-2-infected hamsters.
Keywords: COVID-19; animal models; immune plasma; transfusion.
. 2024 Jan 12:jiad568.
doi: 10.1093/infdis/jiad568. Online ahead of print. Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters
Timothy D Carroll[SUP] 1 2 [/SUP], Talia Wong[SUP] 1 [/SUP], Mary Kate Morris[SUP] 3 [/SUP], Clara Di Germanio[SUP] 4 [/SUP], Zhong-Min Ma[SUP] 2 [/SUP], Mars Stone[SUP] 4 [/SUP], Erin Ball[SUP] 1 [/SUP], Linda Fritts[SUP] 1 2 [/SUP], Arjun Rustagi[SUP] 5 [/SUP], Graham Simmons[SUP] 4 [/SUP], Michael Busch[SUP] 4 [/SUP], Christopher J Miller[SUP] 1 2 6 [/SUP]
Affiliations
- PMID: 38213276
- DOI: 10.1093/infdis/jiad568
Definitive data demonstrating the utility of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) for treating immunocompromised patients remains elusive. To better understand the mechanism of action of CCP, we studied viral replication and disease progression in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected hamsters treated with CCP obtained from recovered COVID-19 patients that were also vaccinated with an mRNA vaccine, hereafter referred to as Vaxplas. Vaxplas transiently enhanced disease severity and lung pathology in hamsters treated near peak viral replication due to immune complex and activated complement deposition in pulmonary endothelium, and recruitment of M1 proinflammatory macrophages into the lung parenchyma. However, aside from one report, transient enhanced disease has not been reported in CCP recipient patients, and the transient enhanced disease in Vaxplas hamsters may have been due to mismatched species IgG-FcR interactions, infusion timing, or other experimental factors. Despite transient disease enhancement, Vaxplas dramatically reduced virus replication in lungs and improved infection outcome in SARS-CoV-2-infected hamsters.
Keywords: COVID-19; animal models; immune plasma; transfusion.